Just About Anyone Can Sell You GLP-1s Online Now
The timeline from "I have an idea" to "I'm prescribing controlled substances" has collapsed from years to hours. That's not innovation. That's a fire sale on public health.
Consider the resume of the newest GLP-1 dispensers: a Q&A site that helps you fix your garbage disposal. A gay dating app. A company that rents chairs to hairdressers. A toe fungus enthusiast with a digital marketing background. These aren't healthcare companies. They're brands that noticed a revenue stream and bought the infrastructure to exploit it — infrastructure that companies like CareValidate, WhiteLabelMD, OpenLoop, and Fuse Health are all too happy to sell them.
"Three hours to go live," Fuse Health brags. They timed it. Of course they did.
We've seen this movie before. In the late 2010s, the "pill mill" model migrated online via rosy-cheeked startups like Roman and Hims, which normalized the idea that a three-minute asynchronous questionnaire constituted a medical relationship. Regulators yawned. Investors cheered. The playbook was validated: medicine could be unbundled from clinicians, repackaged as consumer tech, and scaled like SaaS.
But GLP-1s aren't hair loss pills or ED meds. These are potent metabolic regulators with real side effect profiles — gastroparesis, pancreatitis, thyroid tumor risks in animal studies, and a black-box warning for medullary thyroid carcinoma. They require titration, monitoring, and a clinician who actually knows your history. The fact that a chair-rental company can now dispense them via a rented doctor on a rented platform should terrify anyone who understands how healthcare is supposed to work.
The turnkey vendors will tell you they're solving access. That's the same language Uber used about transportation and Airbnb used about housing — right up until the externalities became impossible to ignore. Access without accountability isn't healthcare. It's distribution.
And distribution is exactly what Jiten Chhabra, CareValidate's CMO, is selling. "Telehealth for everything," he calls it. One launch a day, minimum. His client list includes Bodybuilding.com — a supplement retailer now in the peptide game — alongside the aforementioned cosmetics brand and chair-rental outfit. The toe fungus guy? He spotted search volume. That was his clinical qualification. Keyword research.
Andy Kurtzig of JustAnswer says ChatGPT advised him to enter the GLP-1 market. Let that sink in. The CEO of a publicly traded company made a strategic healthcare pivot based on a large language model's suggestion, and the only barrier to execution was finding a vendor who could handle the pesky medical parts. WhiteLabelMD obliged.
Grindr's Woodwork vertical uses OpenLoop. The dating app that built its empire on proximity now wants to be your proximity to semaglutide. The synergy is almost impressive in its cynicism: a user base already primed for body optimization, a trusted brand, and zero clinical infrastructure of their own. Why build when you can rent?
Scott Roth of LegitScript — the certification body that's supposed to separate legitimate telehealth from the grifters — admits the game is changing. But certification is a snapshot. It validates the structure at a moment in time. It doesn't audit the 2 a.m. prescribing habits of a moonlighting nurse practitioner handling volume for five different "clinics" she's never visited. It doesn't catch the patient who doctor-shops across three turnkey brands sharing the same clinician roster.
And they do share rosters. That's the dirty secret of the turnkey model. The same handful of clinicians cycle through dozens of front-end brands, their names and licenses the only connective tissue between a dating app, a Q&A site, and a bodybuilding forum. The patient thinks they're seeing "Dr. Smith from Woodwork." Dr. Smith is also seeing patients for JustAnswer, Bodybuilding.com, and the toe fungus guy.
This isn't telehealth. It's multi-tenant prescribing with a UI layer.
The FDA has been slow to act on compounded GLP-1s — the legal gray zone where most of these turnkey operations live. The major manufacturers (Novo, Lilly) are suing. State medical boards are overwhelmed. The Ryan Haight Act, which requires an in-person visit before prescribing controlled substances via telemedicine, has been waived since COVID and shows no sign of returning. The regulatory moat has been drained.
Meanwhile, the incentives are perfectly aligned for volume. Turnkey vendors make money per launch. Clinicians make money per consult. Brands make money per subscription. The patient gets a box of pens and a "congrats on your journey" email. Nobody in this chain loses money if the patient develops gastroparesis six months later — except the patient.
We used to call this "corporate practice of medicine" and it was illegal in most states. The turnkey model found the workaround: the clinical entity is technically separate, owned by a friendly physician group, while the brand handles "marketing and technology." It's a legal fiction held together by management services agreements and hope. Courts have started piercing this veil in other contexts. They'll get here eventually.
But eventually is too late for the woman who starts tirzepatide because a Grindr banner ad told her it's "hot girl summer prep," titrates too fast on a protocol written by a committee, and ends up in the ER with severe pancreatitis — only to discover her prescribing "clinic" is a Nevada LLC with no assets, owned by a Delaware holding company, managed by a software vendor in Austin.
The GLP-1 boom created a gold rush. The turnkey vendors are selling pickaxes. And right now, literally anyone with a Stripe account and a dream can buy one.
That's not democratizing healthcare. That's democratizing risk. And the patients are the ones holding the bag.